Shares of UCB SA (OTCMKTS:UCBJY – Get Free Report) passed above its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of $88.80 and traded as high as $92.34. UCB shares last traded at $91.70, with a volume of 3,768 shares trading hands.
UCB Price Performance
The firm’s fifty day moving average price is $88.99 and its 200-day moving average price is $76.87.
UCB Company Profile
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.
Featured Articles
- Five stocks we like better than UCB
- Comparing and Trading High PE Ratio Stocks
- 3 Mid-Cap Stocks Under $20 With Insider Buying and Major Upside
- What Are Dividend Contenders? Investing in Dividend Contenders
- China’s EV Rally: Should Investors Chase, Avoid, or Buy the Dip?
- What does consumer price index measure?
- MarketBeat Week in Review – 10/7 – 10/11
Receive News & Ratings for UCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB and related companies with MarketBeat.com's FREE daily email newsletter.
